1
|
Yang JL, Ma YH, Li YH, Zhang YP, Tian HC, Huang YC, Li Y, Chen W, Yang LJ. Design, Synthesis, and Anticancer Activity of Novel Trimethoxyphenyl-Derived Chalcone-Benzimidazolium Salts. ACS OMEGA 2019; 4:20381-20393. [PMID: 31815242 PMCID: PMC6894157 DOI: 10.1021/acsomega.9b03077] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 11/06/2019] [Indexed: 05/05/2023]
Abstract
A series of novel trimethoxyphenyl-derived chalcone-benzimidazolium salts were synthesized. The biological properties of the compounds were screened in vitro against five different human tumor cell lines. The results suggest that the 5,6-dimethyl-benzimidazole or 2-methyl-benzimidazole ring as well as the 2-naphthylmethyl, 4-methylbenzyl, or 2-naphthylacyl substituent at position-3 of the benzimidazole ring was important to the cytotoxic activity. Notably, (E)-5,6-dimethyl-3-(naphthalen-2-ylmethyl)-1-(3-(4-(3-(3,4,5-trimethoxyphenyl)acryloyl)phenoxy)propyl)-1H-benzo[d]imidazol-3-ium bromide (7f) was more selective to HL-60, MCF-7, and SW-480 cell lines with IC50 values 8.0-, 11.1-, and 5.8-fold lower than DDP. Studies of the antitumor mechanism of action showed that compound 7f could induce cell-cycle G1 phase arrest and apoptosis in SMMC-7721 cells.
Collapse
Affiliation(s)
- Jun-Li Yang
- Key
Laboratory of Medicinal Chemistry for Natural Resources, Ministry
of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China
- School
of Chemistry & Environment, Engineering Research Center for Green
Preparation Technology of Biobased Materials, Yunnan Minzu University, Kunming 650500, P. R. China
| | - Yong-Hui Ma
- Key
Laboratory of Medicinal Chemistry for Natural Resources, Ministry
of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China
| | - Yan-Hua Li
- School
of Chemistry & Environment, Engineering Research Center for Green
Preparation Technology of Biobased Materials, Yunnan Minzu University, Kunming 650500, P. R. China
| | - Yi-Peng Zhang
- Key
Laboratory of Medicinal Chemistry for Natural Resources, Ministry
of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China
| | - Hong-Chang Tian
- Key
Laboratory of Medicinal Chemistry for Natural Resources, Ministry
of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China
| | - Yuan-Cheng Huang
- Key
Laboratory of Medicinal Chemistry for Natural Resources, Ministry
of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China
| | - Yan Li
- State
Key Laboratory for Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Science, Kunming 650204, P. R. China
| | - Wen Chen
- Key
Laboratory of Medicinal Chemistry for Natural Resources, Ministry
of Education and Yunnan Province, School of Chemical Science and Technology, Yunnan University, Kunming 650091, P. R. China
- E-mail: (W.C.)
| | - Li-Juan Yang
- School
of Chemistry & Environment, Engineering Research Center for Green
Preparation Technology of Biobased Materials, Yunnan Minzu University, Kunming 650500, P. R. China
- E-mail: (L.-J.Y.)
| |
Collapse
|
2
|
Zhang CB, Liu Y, Liu ZF, Duan SZ, Li MY, Chen W, Li Y, Zhang HB, Yang XD. Synthesis and cytotoxic activity of novel tetrahydrobenzodifuran–imidazolium salt derivatives. Bioorg Med Chem Lett 2017; 27:1808-1814. [DOI: 10.1016/j.bmcl.2017.02.053] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Revised: 02/10/2017] [Accepted: 02/22/2017] [Indexed: 01/13/2023]
|
3
|
Zhou Y, Duan K, Zhu L, Liu Z, Zhang C, Yang L, Li M, Zhang H, Yang X. Synthesis and cytotoxic activity of novel hexahydropyrrolo[2,3- b ]indole imidazolium salts. Bioorg Med Chem Lett 2016; 26:460-465. [DOI: 10.1016/j.bmcl.2015.11.092] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2015] [Revised: 11/21/2015] [Accepted: 11/25/2015] [Indexed: 11/26/2022]
|
4
|
Xu XL, Yu CL, Chen W, Li YC, Yang LJ, Li Y, Zhang HB, Yang XD. Synthesis and antitumor activity of novel 2-substituted indoline imidazolium salt derivatives. Org Biomol Chem 2015; 13:1550-7. [PMID: 25491254 DOI: 10.1039/c4ob02385d] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
A series of novel 2-substituted indoline imidazolium salt derivatives has been prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that the existence of a substituted benzimidazole ring and substitution of the imidazolyl-3-position with a naphthylacyl or 2-naphthylmethyl group were vital for modulating the cytotoxic activity. Compound 25 was found to be the most potent derivative with IC50 values of 0.24-1.18 μM, and exhibited cytotoxic activity selectively against MCF-7, SW480, SMMC-7721 and HL-60 cell lines, while compound 26 showed powerful inhibitory activities selectively against SMMC-7721 and A549 cell lines. Compound 25 can induce G2/M phase cell cycle arrest and apoptosis in SMMC-7721 cells.
Collapse
Affiliation(s)
- Xiao-Liang Xu
- Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming, 650091, P. R. China.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Xu XL, Wang J, Yu CL, Chen W, Li YC, Li Y, Zhang HB, Yang XD. Synthesis and cytotoxic activity of novel 1-((indol-3-yl)methyl)-1H-imidazolium salts. Bioorg Med Chem Lett 2014; 24:4926-30. [PMID: 25301771 DOI: 10.1016/j.bmcl.2014.09.045] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Revised: 08/22/2014] [Accepted: 09/16/2014] [Indexed: 12/15/2022]
Abstract
A series of novel 1-((indol-3-yl)methyl)-1H-imidazolium salts were prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that the 5,6-dimethyl-benzimidazole ring, and substitution of the imidazolyl-3-position with a naphthylacyl or 4-bromophenacyl group, were vital for modulating inhibitory activity of cell growth. In particular, 1-((N-Boc-indol-3-yl)methyl)-3-(2-naphthylacyl)-1H-5,6-dimethyl-benzimidazolium bromide was found to be the most potent derivative and more selective against myeloid liver carcinoma (SMMC-7721), lung carcinoma (A549) and breast carcinoma (MCF-7), with IC50 values 1.9-fold, 1.7-fold and 4.8-fold lower than DDP. This compound can induce significant cell apoptosis in SMMC-7721 cells.
Collapse
Affiliation(s)
- Xiao-Liang Xu
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China
| | - Jia Wang
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China
| | - Chun-Lei Yu
- State Key Laboratory for Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Science, Kunming 650204, PR China
| | - Wen Chen
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China
| | - Ying-Chao Li
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China
| | - Yan Li
- State Key Laboratory for Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Science, Kunming 650204, PR China.
| | - Hong-Bin Zhang
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China.
| | - Xiao-Dong Yang
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China.
| |
Collapse
|
6
|
Sun CJ, Chen W, Li Y, Liu LX, Wang XQ, Li LJ, Zhang HB, Yang XD. Design, synthesis and antitumor activity of novel 8-substituted 2,3,5,6-tetrahydrobenzo[1,2-b:4,5-b′]difuran imidazolium salt derivatives. RSC Adv 2014. [DOI: 10.1039/c3ra43183e] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A series of novel 8-substituted 2,3,5,6-tetrahydrobenzo[1,2-b:4,5-b′]difuran imidazolium salt derivatives were synthesized and their antitumor structure–activity relationship studies were reported.
Collapse
Affiliation(s)
- Cheng-Jun Sun
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| | - Wen Chen
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| | - Yan Li
- State Key Laboratory for Phytochemistry and Plant Resources in West China
- Kunming Institute of Botany
- Chinese Academy of Science
- Kunming, P.R. China
| | - Lan-Xiang Liu
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| | - Xue-Quan Wang
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| | - Li-Juan Li
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| | - Hong-Bin Zhang
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| | - Xiao-Dong Yang
- Key Laboratory of Medicinal Chemistry for Natural Resource
- Ministry of Education
- School of Chemical Science and Technology
- Yunnan University
- Kunming, P.R. China
| |
Collapse
|
7
|
Chen W, Deng XY, Li Y, Yang LJ, Wan WC, Wang XQ, Zhang HB, Yang XD. Synthesis and cytotoxic activities of novel hybrid 2-phenyl-3-alkylbenzofuran and imidazole/triazole compounds. Bioorg Med Chem Lett 2013; 23:4297-302. [PMID: 23800685 DOI: 10.1016/j.bmcl.2013.06.001] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2013] [Revised: 05/22/2013] [Accepted: 06/01/2013] [Indexed: 11/26/2022]
Abstract
A series of novel hybrid compounds of 2-phenyl-3-alkylbenzofuran and imidazole or triazole were prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that the 2-ethyl-imidazole ring, and substitution of the imidazolyl-3-position with a 2-bromobenzyl or naphthylacyl group, were vital for modulating inhibitory activity. In particular, hybrid compound 31 was found to be the most potent derivative with IC₅₀ values of 0.08-0.55 μM against five strains human tumor cell lines and was found to be more selective against breast carcinoma (MCF-7) and colon carcinoma (SW480) (IC₅₀ values 40.8-fold and 40.1-fold lower than cisplatin (DDP)).
Collapse
Affiliation(s)
- Wen Chen
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Aonofriesei F, Lupsor S. Inhibitory Potential of a Novel Imidazole Derivative as Evaluated by Time-Kill and Dehydrogenase Activity. Curr Microbiol 2012; 66:162-8. [DOI: 10.1007/s00284-012-0252-y] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2012] [Accepted: 10/01/2012] [Indexed: 11/29/2022]
|
9
|
Design, synthesis and cytotoxic activities of novel hybrid compounds between 2-phenylbenzofuran and imidazole. Bioorg Med Chem Lett 2012; 22:2726-9. [PMID: 22440627 DOI: 10.1016/j.bmcl.2012.02.094] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2012] [Revised: 02/27/2012] [Accepted: 02/28/2012] [Indexed: 11/22/2022]
Abstract
A series of novel hybrid compounds between 2-phenylbenzofuran and imidazole have been prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that substitution of the imidazolyl-3-position with a naphthylacyl or bromophenacyl group, were vital for modulating cytotoxic activity. In particular, hybrid compound 15 was found to be the most potent compound against 4 strains human tumor cell lines and more active than cisplatin (DDP), and exhibited cytotoxic activity selectively against liver carcinoma (SMMC-7721).
Collapse
|
10
|
Song WJ, Yang XD, Zeng XH, Xu XL, Zhang GL, Zhang HB. Synthesis and cytotoxic activities of novel hybrid compounds of imidazole scaffold-based 2-substituted benzofurans. RSC Adv 2012. [DOI: 10.1039/c2ra20376f] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
11
|
Chen W, Yang XD, Li Y, Yang LJ, Wang XQ, Zhang GL, Zhang HB. Design, synthesis and cytotoxic activities of novel hybrid compounds between dihydrobenzofuran and imidazole. Org Biomol Chem 2011; 9:4250-5. [PMID: 21505704 DOI: 10.1039/c1ob05116d] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
A series of novel hybrid compounds between dihydrobenzofuran and imidazole has been prepared and evaluated in vitro against a panel of human tumor cell lines. The results suggest that substitution of the imidazolyl-1-position with an electron-donating dihydrobenzofuran, and the imidazolyl-3-position with a naphthylacyl or electron-rich phenacyl group, were vital for modulating cytotoxic activity.
Collapse
Affiliation(s)
- Wen Chen
- Key Laboratory of Medicinal Chemistry for Natural Resource, Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming, 650091, PR China
| | | | | | | | | | | | | |
Collapse
|
12
|
Synthesis and antitumor activity of 1-mesityl-3-(2-naphthoylmethano)-1H-imidazolium bromide. Bioorg Med Chem Lett 2010; 20:1844-7. [DOI: 10.1016/j.bmcl.2010.01.163] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2009] [Revised: 01/27/2010] [Accepted: 01/30/2010] [Indexed: 11/20/2022]
|
13
|
Peretto I, Petrillo P, Imbimbo BP. Medicinal chemistry and therapeutic potential of muscarinic M3 antagonists. Med Res Rev 2010; 29:867-902. [PMID: 19399831 DOI: 10.1002/med.20158] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Muscarinic acetylcholine receptors belong to the G-protein-coupled receptors family. Currently five different receptor subtypes have been identified and cloned. M3 receptor subtypes are coupled to G(q) family proteins and increase phosphatidyl inositol hydrolysis and calcium release from internal stores. They are widely distributed both in the central nervous system and in the periphery. At the central level, M3 receptor subtypes are involved in modulation of neurotransmitter release, temperature homeostasis, and food intake, while in the periphery they induce smooth muscle contraction, gland secretion, indirect relaxation of vascular smooth muscle, and miosis. The main therapeutic applications of M3 antagonists include overactive bladder (OAB), chronic obstructive pulmonary disease (COPD), and pain-predominant irritable bowel syndrome (IBS). The introduction of selective M3 antagonists has not improved clinical efficacy compared with the old non-selective antimuscarinics but has reduced the rate of adverse events mediated by the blockade of cardiac M2 receptors (tachycardia) and central M1 receptors (cognitive impairment). Improved tolerability has been obtained also with controlled release or with inhaled formulations. However, there is still a need for safer M3 antagonists for the treatment of COPD and better-tolerated and more effective compounds for the therapy of OAB. New selective muscarinic M3 antagonists currently in early discovery and under development have been designed to address these issues. However, as M3 receptors are widely located in various tissues including salivary glands, gut smooth muscles, iris, and ciliary muscles, further clinical improvements may derive from the discovery and the development of new compounds with tissue rather than muscarinic receptor subtype selectivity.
Collapse
|
14
|
Skalický M, Rybáčková M, Kysilka O, Kvíčalová M, Cvačka J, Čejka J, Kvíčala J. Synthesis of bis(polyfluoroalkylated)imidazolium salts as key intermediates for fluorous NHC ligands. J Fluor Chem 2009. [DOI: 10.1016/j.jfluchem.2009.07.015] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Wan Z, Laine DI, Yan H, Zhu C, Widdowson KL, Buckley PT, Burman M, Foley JJ, Sarau HM, Schmidt DB, Webb EF, Belmonte KE, Palovich M. Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD. Bioorg Med Chem Lett 2009; 19:4560-2. [DOI: 10.1016/j.bmcl.2009.07.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2009] [Revised: 06/26/2009] [Accepted: 07/02/2009] [Indexed: 10/20/2022]
|
16
|
Yang XD, Zeng XH, Zhang YL, Qing C, Song WJ, Li L, Zhang HB. Synthesis and cytotoxic activities of novel phenacylimidazolium bromides. Bioorg Med Chem Lett 2009; 19:1892-5. [PMID: 19269816 DOI: 10.1016/j.bmcl.2009.02.065] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2009] [Revised: 02/11/2009] [Accepted: 02/16/2009] [Indexed: 11/28/2022]
Abstract
A series of novel phenacylimidazolium derivatives, bearing an aryl or alkyl substituent at position-1 and a phenacyl substituent at position-3 of the imidazole ring, has been prepared and evaluated in vitro against a panel of human tumor cell lines. Phenacylimidazolium bromides bearing a highly sterically hindered aryl group at position-1 and an electron-rich phenacyl or naphthylacyl substituent at position-3 of imidazole ring proved to be more active than imidazolium bromides with other substituted groups. In particular, compound 5j was found to be the most potent compounds with IC(50) values lower than 5.0 microM against 8 strains human tumor cell lines and more active than cisplatin (DDP).
Collapse
Affiliation(s)
- Xiao-Dong Yang
- Key Laboratory of Medicinal Chemistry for Natural Resource (Yunnan University), Ministry of Education, School of Chemical Science and Technology, Yunnan University, Kunming 650091, PR China
| | | | | | | | | | | | | |
Collapse
|
17
|
Kanayama N, Kanari C, Masuda Y, Ohmori S, Ooie T. Drug–drug interactions in the metabolism of imidafenacin: Role of the human cytochrome P450 enzymes and UDP-glucuronic acid transferases, and potential of imidafenacin to inhibit human cytochrome P450 enzymes. Xenobiotica 2008; 37:139-54. [PMID: 17484517 DOI: 10.1080/00498250601140072] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Imidafenacin (IM), 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide, is a newly synthesized antimuscarinic drug developed for the treatment of overactive bladder. To predict clinically relevant drug interactions in the metabolism of IM, the paper investigated: (1) the major enzymes responsible for the metabolism of IM, (2) the effects of concomitant drugs on the inhibition of metabolism of IM, and (3) the effects of IM and its metabolites on the inhibition of human cytochrome P450 (CYP). The elimination of IM and production of oxidative metabolites were mainly catalysed by recombinant CYP3A4, and the elimination of IM by human liver microsomes (HLM) was markedly inhibited by co-incubation with ketoconazole. The production of the N-glucuronide metabolite was only catalysed by recombinant UGT1A4. Clinically established CYP3A4 inhibitors including itraconazole, ketoconazole, erythromycin and clarithromycin inhibited the elimination of IM in HLM. IM and its major metabolites did not affect the activities of CYP enzymes in vitro. The results suggest that the major enzymes responsible for the metabolism of IM are CYP3A4 and UGT1A4, and oxidative metabolism of IM is reduced by concomitant administration of CYP3A4 inhibitors. In contrast, IM and its metabolites have no inhibitory effect on the CYP-mediated metabolism of concomitant drugs.
Collapse
Affiliation(s)
- N Kanayama
- Kyorin Pharmaceutical Co. Ltd, Research Center, Nogi-machi, Shimotsuga-gun, Japan.
| | | | | | | | | |
Collapse
|
18
|
Masuda Y, Kanayama N, Manita S, Ohmori S, Ooie T. Development and validation of bioanalytical methods for Imidafenacin (KRP-197/ONO-8025) and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853:70-9. [PMID: 17387045 DOI: 10.1016/j.jchromb.2007.02.047] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2006] [Revised: 01/26/2007] [Accepted: 02/23/2007] [Indexed: 11/26/2022]
Abstract
Imidafenacin (KRP-197/ONO-8025, IM), 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide, is a new antimuscarinic agent currently under application for the indication of treatment of overactive bladder in Japan. We developed and validated the sensitive and selective bioanalytical methods for the extremely low levels of IM and its metabolite, M-2 (Method 1), M-4 (Method 2) and M-9 (Method 3) in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In each method, plasma sample was extracted by solid phase extraction, separated on a semi-micro high performance liquid chromatography column and detected by tandem mass spectrometer with an atmospheric pressure chemical ionization or ionspray interface. Selected reaction monitoring mode was used for quantification. Each method was found to have acceptable accuracy, precision, stability, selectivity and linearity over the concentration range of 10-500 pg/mL for IM and M-2, 10-1000 pg/mL for M-4 and 50-5000 pg/mL for M-9. Using these analytical methods, concentration profiles of IM and its metabolites in human plasma were successfully determined even in the low pg/mL levels after oral administration of IM at the therapeutic dosage of 0.1 mg.
Collapse
Affiliation(s)
- Yuichi Masuda
- Research Center, Kyorin Pharmaceutical Co. Ltd., 1848 Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
| | | | | | | | | |
Collapse
|
19
|
Masuda Y, Kanayama N, Manita S, Ohmori S, Ooie T. Development and validation of bioanalytical methods for imidafenacin (KRP-197/ONO-8025) and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21:940-8. [PMID: 17474137 DOI: 10.1002/bmc.837] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
New bioanalytical methods have been developed for the determination of imidafenacin (KRP-197/ONO-8025, IM), a novel antimuscarinic drug developed for the treatment of overactive bladder, and its metabolites, M-2, M-3, M-4, M-6 and M-8 (method 1), M-5 and M-9 (method 2) in human urine by using liquid chromatography-tandem mass spectrometry. In each method, the urine sample was extracted by solid-phase extraction, separated on a semi-micro high-performance liquid chromatography column using gradient elution and detected by tandem mass spectrometer with an atmospheric pressure chemical ionization or ionspray interface. Extraction recoveries of IM and metabolites were 81.4% or more. Calibration curves had good linearity in the concentration ranges 0.2-50 ng/mL for IM, M-2, M-3, M-4, M-6 and M-8 (method 1) and 1-250 ng/mL for M-5 and M-9 (method 2), respectively. The accuracy and precision in the intra-day and inter-day reproducibility tests were within +/-17.0 and 16.1% at the lowest concentrations, and within +/-12.8 and 11.1% at higher concentrations, respectively. Using these analytical methods, excretion profiles of IM and its metabolites in human urine were successfully determined after oral administration of IM at the therapeutic dosage of 0.1 mg.
Collapse
Affiliation(s)
- Yuichi Masuda
- Research Center, Kyorin Pharmaceutical Co. Ltd, 1848, Nogi, Nogi-machi, Shimotsuga-gun, Tochigi 329-0114, Japan.
| | | | | | | | | |
Collapse
|
20
|
N-monosubstituted 6-Aminomethylene-5-oxo-2-phenyl-5,6,7,8-tetrahydroquinazolines. Chem Heterocycl Compd (N Y) 2005. [DOI: 10.1007/s10593-005-0278-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
De Amici M, Conti P, Fasoli E, Barocelli E, Ballabeni V, Bertoni S, Impicciatore M, Roth BL, Ernsberger P, De Micheli C. Synthesis and in vitro pharmacology of novel heterocyclic muscarinic ligands. ACTA ACUST UNITED AC 2003; 58:739-48. [PMID: 13679167 DOI: 10.1016/s0014-827x(03)00113-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
A set of novel heterocyclic ligands (7a-9a, 7b-9b, and 9c) structurally related to oxotremorine 2 was designed, synthesized, and tested at muscarinic receptor subtypes. In the binding experiments at cloned hm1-5, the presence of the 2-methylimidazole/2-methyl-3-alkylimidazolium moiety in place of the pyrrolidine ring revealed, in derivatives 8a, 8b, and 9c, a moderate selectivity for some receptor subtypes. The functional in vitro assays yielded results that correlated closely to binding data. In general, on passing from agonists bearing the pyrrolidine moiety to their analogues carrying the 2-methylimidazole function, the overall pharmacological efficacy profile is shifted from agonism toward partial agonism. The insertion of the 2-methyl-3-alkylimidazolium moiety advances the effect such that the compounds are pure antagonists. Quite similarly, chiral 3-oxo-Delta(2)-isoxazoline (+/-)-10 behaved as a weak antagonist unable to discriminate the different muscarinic receptor subtypes.
Collapse
Affiliation(s)
- Marco De Amici
- Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, Viale Abruzzi 42, Milan 20131, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Miyachi H, Nagatsu Y. Biomimetic oxidation of 2-methylimidazole derivative with a chemical model system for cytochrome P-450. Chem Pharm Bull (Tokyo) 2002; 50:1137-40. [PMID: 12192156 DOI: 10.1248/cpb.50.1137] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A chemical model system for cytochrome P-450, consisting of tetraphenylporphyrin manganese chloride (TPPMnCl) and iodosylbenzene, efficiently oxidized 2-methylimidazole to 2-methylimidazolone. This system was next applied to 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutyramide, a muscarinic acetylcholine receptor antagonist under clinical trial, affording the previously unisolated imidazole ring 5-mono-oxidized derivative that is considered to be the precursor of the main metabolites. This system, which is superior to the copper-ascorbate system, should be applicable to in vitro studies of various drugs containing the 2-methylimidazole moiety.
Collapse
Affiliation(s)
- Hiroyuki Miyachi
- Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
| | | |
Collapse
|